trial

Treatment of Negative Symptoms and Schizophrenia

NCTId NCT02204787
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 60 (estimated)
Sponsored by University Hospital, Montpellier
Primary completion 2018-10-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-04-01
Primary completion
2018-10-26
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
transcranial direct current stimulation

Sponsors

University Hospital, MontpellierLead Sponsor

Investigators

1
Jerome ATTAL, MDPrincipal Investigator

Sites

1 total
Montpellier, France

Linked catalysts

1
Treatment of Negative Symptoms and Schizophrenia — primary completion2018-10-26

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE1,PHASE2
Primary Completion Date
2018-10-26
Status
COMPLETED
relationships
The graph out of here
drug
transcranial direct current stimulation
drug
lead_sponsor
University Hospital, Montpellier
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jerome ATTAL, MD
person